Cosmo NVCMOPF -2.20%82 EV-to-FCF is -58.90 as of Jun. 29, 2026. GuruFocus rates CMOPF with a GF Score™ of 82/100 and a GF Value™ of $53.54 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 559 Drug Manufacturers companies, Cosmo NV ranks worse than 178890.7% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Cosmo NV's Enterprise Value is $1,235.2 Mil.
Cosmo NV's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-21.0 Mil. Therefore, Cosmo NV's EV-to-FCF for today is -58.90.
The historical rank and industry rank for Cosmo NV's EV-to-FCF or its related term are showing as below:
CMOPF'
s EV-to-FCF Range Over the Past 10 Years
Min: -107.46 Med: 15.18 Max: 689.47
Current: -58.9
During the past 13 years, the highest EV-to-FCF of Cosmo NV was 689.47. The lowest was -107.46. And the median was 15.18.
CMOPF's EV-to-FCF is ranked worse than 100% of 559
companies
in the Drug Manufacturers industry
Industry Median: 20.02
vs CMOPF: -58.90
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cosmo NV's share price for today is $80.20.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cosmo NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.262.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Cosmo NV EV-to-FCF Related Terms
Cosmo NV EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Cosmo NV's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Cosmo NV's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosmo NV EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cosmo NV's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Cosmo NV's EV-to-FCF falls into.
Cosmo NV's current Enterprise Value is $1,235.2 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cosmo NV's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-21.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosmo NV (CMOPF) has a EV-to-FCF of -58.90 as of Jun. 29, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Cosmo NV and its competitors. According to the industry distribution chart, Cosmo NV ranks #999999 out of 559 companies in the Drug Manufacturers industry.
Is Cosmo NV's EV-to-FCF too high?
Cosmo NV's current EV-to-FCF is -58.90. Based on the distribution chart, Cosmo NV ranks #999999 out of 559 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cosmo NV has a GF Score™ of 82/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cosmo NV's EV-to-FCF compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Cosmo NV ranks #999999 out of 559 companies for EV-to-FCF. This places Cosmo NV in the lower half of its industry. The industry median EV-to-FCF is 20.02. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.02, based on 559 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Cosmo NV and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosmo NV's current EV-to-FCF is -58.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosmo NV stock overvalued right now?
Based on GuruFocus' analysis, Cosmo NV (CMOPF) is currently considered Significantly Overvalued. The stock's GF Value™ is $53.54, compared to a current price of $80.20 — trading 49.8% above its estimated fair value. The current EV-to-FCF is -58.90. Cosmo NV's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Cosmo NV (CMOPF), the current EV-to-FCF is -58.90 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosmo NV (CMOPF) Overvalued in 2026?
Based on GuruFocus' analysis, Cosmo NV stock appears to be overvalued.
The current stock price of $80.20 is trading 49.8% above its estimated GF Value™ of $53.54.
GuruFocus considers Cosmo NV to be Significantly Overvalued.
Key valuation signals for CMOPF:
EV-to-FCF: -58.90
GF Value™: $53.54 vs. price of $80.20 (49.8% above fair value)
No single metric tells the full story. See the CMOPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosmo NV is is a life sciences company. The company is focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). The company designs, develops, and manufactures solutions to address critical medical needs. Its technologies are trusted by international pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. The product pipeline includes Eleview, GI Genius, Winlevi, Lialda, Uceris, and others.
82GF Score
Get the complete analysis for CMOPF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMOPF has been successfully added to your 
